Targeted Therapeutic Agent Release for Weight Loss Therapy

• US 20090182303A1
• Filed: 12/18/2008
• Published: 07/16/2009
• Est. Priority Date: 01/14/2008
• Status: Abandoned Application

• Current Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Inventors: Smith, Paul, Walak, Steven, Madden, Michael
• Application Number:
  US12/337,726
• Publication Number:
  US 20090182303A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61F 5/0013 Implantable devices or invasive measures
• CPC Class Codes: A61M 31/002 Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50

Abstract

A method for treating obesity comprises anchoring at a first target site within a body a first therapeutic agent delivery device including a first therapeutic agent reservoir coupled to a first outlet which, when the first device is anchored at the first target site, is positioned adjacent to a first target treatment location within a GI tract of a patient and releasing a first therapeutic agent from the first reservoir via the first outlet.

Claims

1. A method for treating obesity, comprising:

anchoring at a first target site within a body a first therapeutic agent delivery device including a first therapeutic agent reservoir coupled to a first outlet which is positioned adjacent to a first target treatment location within a GI tract of a patient when the first therapeutic agent delivery device is anchored at the first target site; and

releasing a first therapeutic agent from the first reservoir via the first outlet.

2. The method according to claim 1, wherein the first therapeutic agent delivery device includes a pump fluidly coupled between the reservoir and the first outlet to drive the first therapeutic agent out from the first reservoir via the first outlet.

3. The method according to claim 1, wherein the first target site is in one of a stomach and an intestine.

4. The method according to claim 1, wherein, when the first therapeutic agent delivery device is anchored at the first target site, the first outlet opens into a common bile duct.

5. The method according to claim 1, wherein the first target site is a nerve structure in the GI tract.

6. The method according to claim 5, wherein the first target site is a vagus nerve bundle.

7. The method according to claim 1, wherein the first therapeutic agent is one of a lipase inhibitor, a monoamine reuptake inhibitor, a CB₁ receptor blocker and a neutralizer of one of digestive acids and digestive enzymes

8. The method according to claim 2, wherein the pump is an osmotic pump.

9. The method according to claim 1, further comprising the step of implanting the first therapeutic agent delivery device through one of endoscopic, laparoscopic and open surgical procedures.

10. The method according to claim 2, further comprising implanting a second therapeutic agent delivery device at a second target site within the GI tract, the second therapeutic agent delivery device including a second therapeutic agent reservoir fluidly coupled to a second pump and a second outlet of the second pump which is positioned adjacent to a second target site within a GI tract of a patient when anchored at the second target site.

11. The method according to claim 10, wherein the second reservoir includes a second therapeutic agent.

12. The method according to claim 2, further comprising the step of recharging an implanted battery of the pump by inductive coupling to a power source which remains external to a body of the patient.

13. The method according to claim 1, further comprising implanting the therapeutic agent delivery device through a Percutaneous Endoscopic Gastrostomy (PEG) tube.

14. The method according to claim 1, wherein the first therapeutic agent is released by diffusion.

15. An implantable device, comprising:

a therapeutic agent reservoir sized and shaped for implantation within a living body;

a pump sized and shaped for implantation at a target site within the body, the pump being fluidly connected to the reservoir to motivate fluid from the reservoir to an outlet of the pump wherein, when implanted at a target site within the body, the outlet is located adjacent to target tissue to be treated by a therapeutic agent included within the reservoir; and

an anchoring element attaching the device to an anatomical structure at the target site in a desired position.

16. The device according to claim 15, wherein the target site is within one of a stomach and an intestine and wherein outer surfaces of the pump and the reservoir are formed of bio-compatible materials selected to resist corrosion due to contact with digestive fluids.

17. The device according to claim 15, wherein outer dimensions of the reservoir and the pump are selected to enable them to pass through a working channel of an endoscope.

18. The device according to claim 15, wherein the therapeutic agent is one of a lipase inhibitor, a monoamine reuptake inhibitor and a CB₁ receptor blocker.

19. The device according to claim 18, wherein the therapeutic agent is selected to alter the behavior of at least one nerve structure in a gastro-intestinal tract.

20. The device according to claim 15, wherein the pump is a mechanical pump and the implantable device further comprises an implantable battery powering the mechanical pump and an induction circuit coupled to the battery for transmitting to the battery power received inductively from an external power source.

21. The device according to claim 15, wherein the pump is an osmotic pump comprising an osmotic layer and a semipermeable membrane, properties of the osmotic layer and the semipermeable membrane being selected relative to properties of tissue adjacent to the target site to control a rate of release of the therapeutic agent.

22. The device according to claim 15, wherein the reservoir is refillable through an externally communicating port.

23. The device according to claim 15, wherein the anchoring element is formed of a material selected to degrade after a predetermined time has elapsed since implantation.

24. The device according to claim 15, wherein the therapeutic agent neutralizes one or both of digestion enzymes and digestive acids.

25. The device according to claim 15, wherein the therapeutic agent interferes with neural signals to digestive organs.

26. A system for treating obesity comprising:

a percutaneous endoscopic gastrostomy (PEG) tube; and

a balloon insertable into a stomach via the PEG tube, at least a portion of a surface of the balloon having a porosity selected to control a rate of elution into the stomach of an inflation fluid supplied to the balloon.

27. The system according to claim 26, further comprising a catheter including an inflation lumen extending therethrough to a distal opening, the balloon being coupled to a distal end of the catheter surrounding the distal opening.

28. A method for treating obesity comprising:

inserting into a GI tract an implant including a therapeutic agent, the therapeutic agent being embedded in one of a degradable portion and a porous portion of the implant for release therefrom at a selected rate; and

anchoring the implant at a target site.

29. The method according to claim 28, wherein the implant is a tablet anchored at the target site using a plurality of hooks formed of a material designed to degrade and release the tablet after a predetermined time has elapsed.

30. The method according to claim 28, wherein the implant is a therapeutic agent eluting stent and wherein the target site is within a common biliary duct, the therapeutic agent comprising one of a lipase inhibitor and a detergent.

31. The method according to claim 30, wherein the therapeutic agent comprises a bile neutralizer.